DEVELOPMENT AND VALIDATION OF A NEW ANALYTICAL REVERSE PHASE- HPLC METHOD FOR THE SIMULTANEOUS DETERMINATION OF LESINURAD AND ALLOPURINOL IN PURE FORM AND MARKETED COMBINED DOSAGE FORM

Pharmacy

A streamlined, repeatable, and effective high-performance liquid chromatographic technique was developed for the simultaneous confirmation of Lesinurad and Allopurinol in pure form and showcased mixed pharmaceutical dosage forms. An isocratic mode column with a symmetry (C18) (150mm x 4.6mm, 5µm) and a flexible buffer consisting of Methanol: Phosphate (pH-3.8) (28:72% v/v) was previously used. Radiation at 252 nm was measured at a flow rate of 1 ml/min. Both Lesinurad and Allopurinol exhibited aid times of 1.794 and 3.440 minutes, respectively, and linearity extends of 10-30 and 10-50 parts per million, respectively. Linearity, accuracy, precision, satisfactoryness, limitation of disclosure, and management of quantification are all qualities that have been praised for the methodology. The limits of detection (LOD) and limits of quantification (LOQ) for Lesinurad were found to be 0.86µg/ml and 2.58µg/ml, respectively, whereas for Allopurinol the values were 1.28µg/ml and 3.84µg/ml. It was found that the produced method was accurate, precise, and applicable to the simultaneous confirmation of Lesinurad and Allopurinol in tablets.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.